Hoffmann-La Roche: Multiple Myeloma trials
The registry lists 30 Multiple Myeloma studies with Hoffmann-La Roche as lead sponsor. 6 are open to participants now and 9 have results posted.
Phase 1 23Phase 2 9Phase 3 2No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple MyelomaRecruitingNCT07825064Phase 2
- A Study to Evaluate RO7851624 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)RecruitingNCT07558915Phase 1
- Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple MyelomaRecruitingNCT07555938Phase 3
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)RecruitingNCT05927571Phase 1
- A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple MyelomaRecruitingNCT05583617Phase 1/2
- A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple MyelomaRecruitingNCT04910568Phase 1
- A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple MyelomaTerminatedNCT06055075Phase 1/2Results posted
- A Study Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple MyelomaCompletedNCT04434469Phase 1Results posted
- A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple MyelomaCompletedNCT03312530Phase 1/2Results posted
- P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)TerminatedNCT03288493Phase 1/2Results posted
- Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple MyelomaTerminatedNCT02739594Phase 3Results posted
- A Study of Avastin (Bevacizumab) in Patients With Multiple MyelomaTerminatedNCT02079519Phase 2Results posted
- A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)CompletedNCT01804140Results posted
- A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive CancersCompletedNCT01524978Phase 2Results posted
- A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)CompletedNCT00473590Phase 2Results posted
- A Clinical Study to Evaluate the Effects of RO7875913 in Healthy Participants and of RO7875913 With Cevostamab in Participants With Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT07342114Phase 1
- A Study Evaluating the Pharmacokinetics, Safety, and Efficacy of Cevostamab in Chinese Participants With Relapsed or Refractory Multiple MyelomaActive, not recruitingNCT06934044Phase 1
- A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT05646836Phase 1
- A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT05535244Phase 1/2
- A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple MyelomaCompletedNCT05243342Phase 1
- P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple MyelomaActive, not recruitingNCT04960579Phase 1
- A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM)CompletedNCT04557150Phase 1
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin LymphomaTerminatedNCT04045028Phase 1
- Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101Active, not recruitingNCT03741127Phase 1
- Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)CompletedNCT03275103Phase 1
- Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor RO6870810 as Mono- and Combination Therapy in Advanced Multiple MyelomaCompletedNCT03068351Phase 1
- A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)CompletedNCT02431208Phase 1
- A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01432353Phase 1
- A Study of the Safety and Pharmacokinetics of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple MyelomaCompletedNCT01122875Phase 1
- A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00664898Phase 1